133 related articles for article (PubMed ID: 7840601)
1. In vitro activities of two new glycylcyclines, N,N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1994 Oct; 38(10):2513-5. PubMed ID: 7840601
[TBL] [Abstract][Full Text] [Related]
2. Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria.
Brown BA; Wallace RJ; Onyi G
Antimicrob Agents Chemother; 1996 Apr; 40(4):874-8. PubMed ID: 8849243
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1994 Nov; 38(11):2628-32. PubMed ID: 7872759
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of DMG-Mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Oct; 12(10):784-6. PubMed ID: 7802861
[TBL] [Abstract][Full Text] [Related]
5. Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines.
Whittington WL; Roberts MC; Hale J; Holmes KK
Antimicrob Agents Chemother; 1995 Aug; 39(8):1864-5. PubMed ID: 7486935
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.
Testa RT; Petersen PJ; Jacobus NV; Sum PE; Lee VJ; Tally FP
Antimicrob Agents Chemother; 1993 Nov; 37(11):2270-7. PubMed ID: 8285606
[TBL] [Abstract][Full Text] [Related]
7. N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci.
Goldstein FW; Kitzis MD; Acar JF
Antimicrob Agents Chemother; 1994 Sep; 38(9):2218-20. PubMed ID: 7811053
[TBL] [Abstract][Full Text] [Related]
8. Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO. Antimicrobial activity studies against gram-positive species.
Johnson DM; Jones RN
Diagn Microbiol Infect Dis; 1996 Jan; 24(1):53-7. PubMed ID: 8988765
[TBL] [Abstract][Full Text] [Related]
9. A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter.
Someya Y; Yamaguchi A; Sawai T
Antimicrob Agents Chemother; 1995 Jan; 39(1):247-9. PubMed ID: 7695316
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of two glycylcyclines against gram-positive bacteria.
Eliopoulos GM; Wennersten CB; Cole G; Moellering RC
Antimicrob Agents Chemother; 1994 Mar; 38(3):534-41. PubMed ID: 8203851
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines.
Tuckman M; Petersen PJ; Projan SJ
Microb Drug Resist; 2000; 6(4):277-82. PubMed ID: 11272255
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
Sum PE; Petersen P
Bioorg Med Chem Lett; 1999 May; 9(10):1459-62. PubMed ID: 10360756
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in tetracycline antibiotics.
Sum PE; Sum FW; Projan SJ
Curr Pharm Des; 1998 Apr; 4(2):119-32. PubMed ID: 10197036
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of two glycylcyclines.
Wise R; Andrews JM
Antimicrob Agents Chemother; 1994 May; 38(5):1096-102. PubMed ID: 8067744
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2011 Jan; 55(1):421-5. PubMed ID: 21041506
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic susceptibility of anaerobic bacteria from the human oral cavity.
Baker PJ; Evans RT; Slots J; Genco RJ
J Dent Res; 1985 Oct; 64(10):1233-44. PubMed ID: 3861655
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines.
Weiss WJ; Jacobus NV; Petersen PJ; Testa RT
J Antimicrob Chemother; 1995 Jul; 36(1):225-30. PubMed ID: 8537270
[TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
20. [Comparative activity of 9 beta-lactamines, clindamycin and metronidazole on strictly anaerobic bacteria].
Derriennic M; Reynaud A; Launay C; Courtieu AL
Pathol Biol (Paris); 1987 May; 35(5):572-6. PubMed ID: 3302862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
